The risk of primary and contralateral breast cancer after ovarian cancer inBRCA1/BRCA2mutation carriers
出版年份 2012 全文链接
标题
The risk of primary and contralateral breast cancer after ovarian cancer inBRCA1/BRCA2mutation carriers
作者
关键词
-
出版物
CANCER
Volume 119, Issue 5, Pages 955-962
出版商
Wiley
发表日期
2012-11-17
DOI
10.1002/cncr.27839
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients
- (2011) P. M. L. H. Vencken et al. ANNALS OF ONCOLOGY
- Preventive therapy for breast cancer: a consensus statement
- (2011) Jack Cuzick et al. LANCET ONCOLOGY
- Therapeutic Approaches for Women Predisposed to Breast Cancer
- (2010) Katherine L. Nathanson et al. Annual Review of Medicine
- Bilateral prophylactic mastectomy in women with inherited risk of breast cancer – Prevalence of pain and discomfort, impact on sexuality, quality of life and feelings of regret two years after surgery
- (2010) Jessica Gahm et al. BREAST
- Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer
- (2010) Kerryn W. Reding et al. BREAST CANCER RESEARCH AND TREATMENT
- Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age
- (2010) Dorina M. van der Kolk et al. BREAST CANCER RESEARCH AND TREATMENT
- Common Breast Cancer Susceptibility Alleles and the Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Implications for Risk Prediction
- (2010) A. C. Antoniou et al. CANCER RESEARCH
- Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and Mortality
- (2010) Susan M. Domchek JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
- (2010) Daniel P. Silver et al. JOURNAL OF CLINICAL ONCOLOGY
- BRCA1-Associated Breast Cancers Present Differently From BRCA2-Associated and Familial Cases: Long-Term Follow-Up of the Dutch MRISC Screening Study
- (2010) Adriana J. Rijnsburger et al. JOURNAL OF CLINICAL ONCOLOGY
- BRCA mutations in the management of breast cancer: the state of the art
- (2010) Steven A. Narod Nature Reviews Clinical Oncology
- Uptake, Time Course, and Predictors of Risk-Reducing Surgeries in BRCA Carriers
- (2009) Mary S. Beattie et al. Genetic Testing and Molecular Biomarkers
- BRCA1 and implications for response to chemotherapy in ovarian cancer
- (2009) Jennifer E. Quinn et al. GYNECOLOGIC ONCOLOGY
- Contralateral Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers
- (2009) Monika K. Graeser et al. JOURNAL OF CLINICAL ONCOLOGY
- Survival Analysis of Cancer Risk Reduction Strategies forBRCA1/2Mutation Carriers
- (2009) Allison W. Kurian et al. JOURNAL OF CLINICAL ONCOLOGY
- Meta-analysis of Risk Reduction Estimates Associated With Risk-Reducing Salpingo-oophorectomy in BRCA1 or BRCA2 Mutation Carriers
- (2009) T. R. Rebbeck et al. JNCI-Journal of the National Cancer Institute
- Predictors of Contralateral Prophylactic Mastectomy in Women With a BRCA1 or BRCA2 Mutation: The Hereditary Breast Cancer Clinical Study Group
- (2008) Kelly A. Metcalfe et al. JOURNAL OF CLINICAL ONCOLOGY
- Risk-Reducing Salpingo-Oophorectomy for the Prevention of BRCA1- and BRCA2-Associated Breast and Gynecologic Cancer: A Multicenter, Prospective Study
- (2008) Noah D. Kauff et al. JOURNAL OF CLINICAL ONCOLOGY
- “BRCAness” Syndrome in Ovarian Cancer: A Case-Control Study Describing the Clinical Features and Outcome of Patients With Epithelial Ovarian Cancer Associated WithBRCA1andBRCA2Mutations
- (2008) David S.P. Tan et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More